All In Biotech

Drug Trial Radar · NCT00636064

A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery

A Double-Blind Multicenter Study of the Safety and Efficacy of Parecoxib Sodium/Valdecoxib and Placebo/Valdecoxib Compared to Placebo for Treatment of Post-Surgical Pain in Patients Who Have Coronary Bypass Graft Via Median Sternotomy

Last checked: Nov 20, 2026Latest source record: Oct 10, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,671 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,671

Actual

Start

Jan 2003

Primary completion

Not stated

Study completion Jan 2004

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 14, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of parecoxib/valdecoxib therapy and placebo/valdecoxib therapy for the treatment of pain after coronary artery bypass surgery

Conditions

  • Pain

Interventions

  • Parecoxib Sodium/ValdecoxibDrug

    Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.

  • Placebo/ValdecoxibDrug

    Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.

  • Placebo/PlaceboOther

    Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Combined incidence of the number of patients with at least 1 confirmed clinically relevant adverse event (CRAE)Time frame: Day 30

Locations

206 sites in 27 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Fairhope, Alabama

  • Pfizer Investigational Site

    Mobile, Alabama

  • Pfizer Investigational Site

    Mobile, Alabama

  • Pfizer Investigational Site

    Mobile, Alabama

  • Pfizer Investigational Site

    Mobile, Alabama

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Fayetteville, Arkansas

  • Pfizer Investigational Site

    Springdale, Arkansas

  • Pfizer Investigational Site

    Anaheim, California

  • Pfizer Investigational Site

    Anaheim, California

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    Orange, California

  • Pfizer Investigational Site

    Sacramento, California

  • Pfizer Investigational Site

    Sacramento, California

  • Pfizer Investigational Site

    San Francisco, California

  • Pfizer Investigational Site

    San Francisco, California

  • Pfizer Investigational Site

    San Francisco, California

  • Pfizer Investigational Site

    Santa Rosa, California

  • Pfizer Investigational Site

    Santa Rosa, California

  • Pfizer Investigational Site

    Stanford, California

  • Pfizer Investigational Site

    Fort Collins, Colorado

  • Pfizer Investigational Site

    Fort Collins, Colorado

  • Pfizer Investigational Site

    New Haven, Connecticut

  • Pfizer Investigational Site

    New Haven, Connecticut

  • Pfizer Investigational Site

    Washington D.C., District of Columbia

  • Pfizer Investigational Site

    Brandon, Florida

  • Pfizer Investigational Site

    Clearwater, Florida

  • Pfizer Investigational Site

    Hudson, Florida

  • Pfizer Investigational Site

    Jacksonville, Florida

  • Pfizer Investigational Site

    Melbourne, Florida

  • Pfizer Investigational Site

    Melbourne, Florida

  • Pfizer Investigational Site

    Pensacola, Florida

  • Pfizer Investigational Site

    Pensacola, Florida

  • Pfizer Investigational Site

    Sarasota, Florida

  • Pfizer Investigational Site

    St. Petersburg, Florida

  • Pfizer Investigational Site

    Tampa, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Augusta, Georgia

  • Pfizer Investigational Site

    Fort Wayne, Indiana

Showing 40 of 206 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.